Share this postStock Region ResearchClinical-stage Biotechnology Company Reveals New Data From Amezalpat StudyCopy linkFacebookEmailNotesMoreClinical-stage Biotechnology Company Reveals New Data From Amezalpat StudyTempest Therapeutics to Unveil New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma.Stock RegionJun 21, 2024∙ PaidShare this postStock Region ResearchClinical-stage Biotechnology Company Reveals New Data From Amezalpat StudyCopy linkFacebookEmailNotesMoreShareThis post is for paid subscribersSubscribeAlready a paid subscriber? Sign inPreviousNext
